Interim CR signal unconfirmed; no durability data yet. Preliminary unblinded data from 45 patients in an adaptive Phase 2/3 trial (MIRACLE Part A) lacks duration-of-remission or OS endpoints; unblinded interim design introduces bias risk, and evidence weight is substantially below completed Phase III thresholds established by successful anthracycline precedents.

Qualitative survival claim; no quantitative Phase 2 data disclosed. Phase 2 NSCLC data presented at ASCO 2026 lack any disclosed endpoint figures — no median OS, hazard ratio, or patient count. Without these, the survival benefit claim cannot be benchmarked against regulatory or HTA thresholds, and evidence weight remains below randomized Phase 2, let alone pivotal standard.

Phase 3 launch; no proof-of-concept data disclosed. No Phase 2 lasofoxifene-plus-abemaciclib combination data are provided. ELAINE-3 is an ongoing Phase 3 trial with enrollment not yet complete and no interim efficacy signal reported, simultaneously testing two biologically unvalidated hypotheses.

No efficacy data; existential financing gap dominates. All therapeutic evidence is pre-efficacy: ReSPECT-LM, ReSPECT-GBM, and ReSPECT-PBC are ongoing with no reported outcomes. CNSide performance rests on case series-level datasets (n=12 and n=15) with no clinical utility demonstration, and $8.6 million cash against $9.1 million quarterly burn creates less than one quarter of runway.

Symptom signal only; no histology, no comparator arm. RESOLVE is a single-arm Phase 1b/2a study reporting symptom outcomes without quantitative efficacy figures, histological endpoints, or a control group. Both precedent approvals in EoE (budesonide Phase 3, dupilumab Phase 3 TREET) required co-primary histological and symptomatic endpoints from randomized controlled trials.

No human data disclosed for either asset. Both ABI-6250 and GS-1179 are pre-Phase 2 with no disclosed mechanisms, Phase 1 safety data, or efficacy signals. The press release announces Phase 2 intent only; all supporting evidence derives from indication-level peers, not asset-specific data.

Safety-only trial; no efficacy data generated. The Phase I/IIa is a 12-patient, open-label, single-arm, dose-escalation study assessing tolerability and safety only. No efficacy endpoints are reported or planned for this stage, and no mechanistic precedent for allogeneic iPS-derived retinal sheet therapy exists in any retinal indication.

Statistically significant Phase II signal, no interpretable data. The LiBBY trial met its primary endpoint but discloses no effect size, safety profile, trial duration, agitation scale, or comparator arm design — all parameters required to assess whether the signal meets regulatory clinical meaningfulness thresholds established in the risperidone precedent or survives the 18–37% placebo response documented in this indication.

Exploratory design; mechanism and comparator dose undisclosed. The OPAL arm is a 64-participant, 24-week randomized study — proof-of-concept scale, not pivotal. Icovamenib's mechanism of action is not disclosed, and the semaglutide comparator dose is unquantified, preventing assessment of whether the study tests benefit over best available therapy.

Phase 2 primary endpoint missed; no data disclosed. AMPLIFY-7P did not meet its primary endpoint with no efficacy metrics released; the 'multiple complete responses' signal driving the Phase 1 pivot lacks disclosed evidence tier, n, or clinical context, placing all forward-looking claims below the threshold of controlled or reproducible evidence.

Single-arm Phase 2b; no durability, safety, or survival data. CLOVER WaM is an uncontrolled single-arm Phase 2b study reporting response rate endpoints only; no duration of response, PFS, OS, or safety data are disclosed, and the confirmatory Phase 3 has not yet enrolled patients, leaving the pivotal evidence package incomplete.

Conference event only; zero efficacy data disclosed. ELAINE-3 is an ongoing Phase 3 trial with no interim, Phase 2, or safety data reported. The announcement is a scientific conference presence notice, not an efficacy readout; topline data are not expected until H2 2027.

First-in-human only; zero clinical safety or efficacy data. SONIX is a single-arm Phase I/II trial with no efficacy, safety, or audiometric data yet reported; initial human findings are not anticipated until end of 2026. Preclinical comparators present mixed signals, and no clinical-stage peer exists to anchor expectations.

Single compassionate-use case; no controlled data. The entire evidence base is one eIND patient with a rare, immune-dependent condition and unmeasured confounders including immunosuppression changes and possible concomitant antibiotic use; the 89% mass reduction is a radiologic surrogate, not a validated antimicrobial endpoint, and no Phase 1 safety or PK/PD data exist.

No CS-AKI efficacy data; prior human trial failed. The sole randomized controlled human trial of LSALT (Phase 2a, 61 subjects, COVID-19) failed its primary endpoint (p=0.86); no efficacy data of any kind exists for the CS-AKI indication, and the current announcement is a site-expansion procedural update only.

Phase 1/2 signal; pivotal replication entirely unproven. All efficacy and safety data derive from a Phase 1/2 study with 4-week follow-up only; the FDA/EMA-required 12-week co-primary endpoint is absent, sample size is unreported, mechanism is undisclosed, and no Phase 3 data exist to establish reproducibility.

First patient dosed; zero efficacy or safety data disclosed. The DREAM study has dosed its first patient in a Phase II investigator-sponsored trial. No IOP reduction figures, safety readouts, comparator arm data, or primary endpoint results exist. No mechanistically comparable precedent supports the cannabinoid-oral route combination in this indication.

Qualitative signal only; no quantitative efficacy data disclosed. The DDW presentation described improvement in fibrosis and inflammation but provided no response rates, eosinophil thresholds, symptom scores, or statistical significance. Evidence tier is Phase 2 or earlier, single-arm or uncontrolled context cannot be confirmed, and no figures are available to benchmark against Phase 3 RCT standards set by budesonide or dupilumab.

Qualitative signals only; no quantified efficacy data. BDC-4182 is in single-arm Phase 1/2 Cohort 4 with no disclosed ORR, PFS, OS, or biomarker endpoint. 'Well tolerated' and 'activity consistent with immune-stimulating mechanism' are descriptive characterizations, not trial outcomes; all approved gastric/GEJ precedents required Phase 3 RCT OS data.

Phase 2a null result; Phase 1 healthy-subject data only. SION-719's PreciSION CF trial produced a -1.0 mmol/L placebo-adjusted sweat chloride change (p=0.7), a pharmacodynamic null. SION-451's evidence base is limited to Phase 1 safety and PK in healthy subjects, with no CF patient efficacy data of any kind.

Cross-strain efficacy claim outpaces available immunogenicity data. The sole mechanistic bridge is low-level cross-reacting binding antibodies to Bundibugyo, explicitly flagged as limited by the WHO TAG-CVP. No functional neutralization data, no Phase II Bundibugyo efficacy data, and no approved comparator exist; the Phase III has not yet been initiated.

Phase 1 safety study only; zero efficacy data. NBIP-1968 has initiated a single ascending dose Phase 1 trial assessing tolerability only. No weight loss, pharmacokinetic, or cardiovascular outcome data exist for this asset; the only mechanistically matched evidence comes from retatrutide's randomized Phase 2, which is a distinct program.

First patient dosed; no efficacy or safety data exist. Phase II initiation with undisclosed trial design, no comparator arm confirmed, and no efficacy, safety, or biomarker data available. All mechanistically comparable approvals required Phase III RCT evidence; this asset has generated none.

Phase 1 signal; no controlled survival data yet. NCT07671339 is a 20-patient single-arm Phase 1 trial with no comparator arm; prior ELI-002 survival correlation data lacks published trial-level detail, and the only Phase 3 RCT in the same neoadjuvant PDAC vaccine setting (algenpantucel-L, n=303) showed HR 1.02, P=0.98 with no survival benefit.

Phase III futility stop; zero efficacy data disclosed. The FLASH2 trial was discontinued at interim analysis with no response rates, durability figures, or safety signals released. No Phase II proof-of-concept dataset was referenced, meaning the pivotal program lacked publicly verifiable foundational evidence, and no endpoint-level outcome can be assessed.

Cross-reactivity unproven; Phase III justified by urgency alone. The WHO recommendation bypasses Phase II and rests on Zaire-strain immunogenicity and safety data, with the advisory group explicitly acknowledging absent cross-reactivity evidence for Bundibugyo — a distinct ebolavirus species with a divergent glycoprotein target. No pivotal efficacy data for this strain exists.

Novel delivery system with a total evidence void. The program is in Phase 3, but no efficacy or safety data for the bimatoprost-IOL system has been released. The entire investment thesis rests on extrapolating from different delivery systems (topical drops, intracameral implants) with known limitations.

Strategic cut obscures unknown clinical profile. The Phase 2 suspension was explicitly for "strategic business reasons," not safety. No efficacy or safety data have been disclosed, making it impossible to independently assess the asset's clinical merit or potential.

Phase II/III initiated with no urothelial proof-of-concept. HARMONi-GU1 is a Phase II/III study with no disclosed ivonescimab data in urothelial carcinoma as monotherapy or in combination with EV; the trial proceeds directly to dose-finding and pivotal evaluation without prior signal generation, and must demonstrate superiority or non-inferiority against a comparator that achieved median OS 31.5 months in a Phase 3 RCT.

First-in-human trial initiation offers no clinical evidence. The evidence is limited to a Phase 1 trial design assessing safety and immunogenicity in ~80 healthy adults. No efficacy, durability, or real-world effectiveness data exists for mRNA-1469.

Inconsistent Phase 2 signals undermine proof-of-concept. The most recent 61-patient randomized Phase 2 study failed to show placebo separation on self-assessed distress in either dose arm, directly contradicting two earlier positive randomized Phase 2 studies; no Phase 3 data exist and the endpoint remains unvalidated for regulatory acceptance in SAD.

Strategy is logical, but supporting evidence is absent. The entire thesis rests on the unpublished DENALI trial hitting efficacy benchmarks set by a competitor's (adavosertib) small, single-arm Phase 2 ovarian cancer subset (n=14), as no azenosertib efficacy data is public.

Unvalidated endpoint undermines otherwise positive Phase IIb signal. SUNRISE-PD is a Phase IIb trial whose primary endpoint, EPNIC-15, is explicitly unrecognized in the broader Parkinson's field; no validated clinical scale results (MDS-UPDRS, PDQ-39, 'Off-time') or effect sizes were disclosed, preventing assessment against established MCIDs or regulatory standards.

Safety gate cleared; no efficacy signal disclosed. The FREEDOM2-DM1 announcement is a Phase II DSMB safety readout only — no efficacy endpoints, biomarker responses, or functional outcomes are reported from the fully enrolled 10mg/kg cohort. Single-arm safety data cannot establish proof of concept.

Asset's value proposition is entirely contingent. The entire HCM program's viability rests on the unreleased Phase 3 SONATA-HCM data. The asset's existing clinical profile is defined by data from different indications (T1D, worsening HF) with significant safety flags and a prior FDA rejection.

Pivotal trial launched on undisclosed early-stage data. The decision to initiate the ~580-patient BrenDeLL-Lung01 trial rests on unpublished Phase I results. The asset's mechanism of action and the trial's control arm composition are not specified, precluding robust risk assessment.

First-patient dosing, zero clinical efficacy or safety data. DISP-10 has dosed its first Phase I patient with no ORR, PFS, OS, or tolerability data reported. No mechanistic precedent clears the combined mechanism-and-clinical-context fit bar; all cited immunotherapy approvals in GI cancers use checkpoint inhibition, not oncolytic virus plus CAR-T, placing this at the lowest evidence tier for any efficacy inference.